X0206 3 2014-12-12 0 0001619551 CB Pharma Acquisition Corp. CNLM 0000941841 ROSENWALD LINDSAY A MD C/O CB PHARMA ACQUISITION CORP. 24 NEW ENGLAND EXECUTIVE PARK, SUITE 105 BURLINGTON MA 01803 1 1 1 0 Co-Chairman and CEO 0001429260 CORONADO BIOSCIENCES INC 24 NEW ENGLAND EXECUTIVE PARK BURLINGTON MA 01803 0 0 1 0 Ordinary Shares 1385000 I by Coronado Biosciences, Inc. Redeemable Warrants 11.50 Ordinary Shares 265000 I by Coronado Biosciences, Inc. Right to Receive Ordinary Shares Ordinary Shares 265000 I by Coronado Biosciences, Inc. Includes securities underlying 265,000 units of the Issuer to be purchased by Coronado Biosciences, Inc. which Coronado Biosciences, Inc. irrevocable committed to purchase prior to the effective date of the registration statement relating to the issuer's initial public offering ("IPO"). Each unit ("Unit") consists of one ordinary share, one right ("Right") to receive one-tenth of one ordinary share upon consummation of the Issuer's initial business combination, and one redeemable warrant ("Warrant") to purchase one half of one ordinary share upon the later of the consummation of the Issuer's initial business combination and 12 months from the effective date of the registration statement relating to the IPO. The purchase is being made on a private placement basis and will be consummated simultaneously with the consummation of the Issuer's IPO. Mr. Rosenwald is the Chairman, President and Chief Executive Officer of Coronado Biosciences, Inc., and as such, controls the voting and disposition of such shares. Mr. Rosenwald disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that Mr. Rosenwald is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The warrants will become exercisable on the later of the completion of an initial business combination and 12 months from the effective date of the registration statement relating to the Issuer's IPO. The warrants shall expire five years after the completion of an initial business combination, or earlier upon redemption. Each Right entitles the holder to receive one-tenth (1/10) of one of the Issuer's ordinary shares upon consummation of the Issuer's initial business combination. If the Issuer fails to consumate an initial business combination within eighteen (18) months from the closing of the Issuer's IPO, the Issuer will be dissolved and the Rights will expire worthless. /s/ Lindsay A. Rosenwald 2014-12-12